{"id":"NCT00856206","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)","officialTitle":"A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate- Lowering Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2011-01","completion":"2011-01","firstPosted":"2009-03-05","resultsPosted":"2017-04-28","lastUpdate":"2017-04-28"},"enrollment":1315,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Gout"],"interventions":[{"type":"BIOLOGICAL","name":"Rilonacept","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Rilonacept 160 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this clinical research study is to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are on urate-lowering therapy. Subjects will participate in this study for approximately 20 weeks. Rilonacept is being studied for use in preventing gout flares in subjects on urate-lowering therapy.","primaryOutcome":{"measure":"Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"Baseline up to Week 20","effectByArm":[{"arm":"Placebo","deltaMin":59.1,"sd":null},{"arm":"Rilonacept 160 mg","deltaMin":66.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":124,"countries":["United States","Germany","India","Indonesia","South Africa","Taiwan"]},"refs":{"pmids":["25028379"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":330},"commonTop":["Headache","Arthralgia","Accidental overdose","Pain in extremity","Injection site erythema"]}}